MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Eli Lilly and Co.

Open

SectorGezondheidszorg

866.8 1.91

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

845.8

Max

871.37

Belangrijke statistieken

By Trading Economics

Inkomsten

7.8B

8.8B

Verkoop

2.1B

14B

K/W

Sectorgemiddelde

70.036

57.333

EPS

5.32

Dividendrendement

0.71

Winstmarge

65.172

Werknemers

47,000

EBITDA

1.2B

6.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+16.73% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.71%

2.63%

Volgende Winsten

1 mei 2025

Volgende Ex Dividend datum

14 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-50B

735B

Vorige openingsprijs

864.89

Vorige sluitingsprijs

866.8

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 apr 2025, 09:26 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18 apr 2025, 15:57 UTC

Belangrijke Marktbewegers

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

17 apr 2025, 11:52 UTC

Belangrijke Marktbewegers

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

9 apr 2025, 18:18 UTC

Belangrijke Marktbewegers

Pharma Shares Reverse Losses After Tariff Pause

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 apr 2025, 23:15 UTC

Belangrijke Marktbewegers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

22 apr 2025, 09:31 UTC

Populaire aandelen

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17 apr 2025, 18:27 UTC

Top Nieuws

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

17 apr 2025, 10:45 UTC

Top Nieuws

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

11 apr 2025, 16:23 UTC

Acquisities, Fusies, Overnames

Novo Remade Denmark. Then Came the Stock Selloff. -2-

11 apr 2025, 16:23 UTC

Acquisities, Fusies, Overnames

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

11 apr 2025, 09:30 UTC

Top Nieuws

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

11 apr 2025, 05:00 UTC

Top Nieuws

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

10 apr 2025, 05:00 UTC

Winsten

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

8 apr 2025, 21:26 UTC

Winsten

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2 apr 2025, 16:53 UTC

Top Nieuws

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 apr 2025, 22:31 UTC

Top Nieuws

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 apr 2025, 21:47 UTC

Top Nieuws

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 mrt 2025, 15:54 UTC

Top Nieuws

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 15:14 UTC

Top Nieuws

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 feb 2025, 14:30 UTC

Top Nieuws

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 feb 2025, 12:00 UTC

Top Nieuws

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Top Nieuws
Winsten

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Winsten

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 feb 2025, 14:32 UTC

Marktinformatie
Winsten

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 feb 2025, 13:18 UTC

Top Nieuws
Winsten

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

16.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,003.6 USD  16.73%

Hoogste 1,124 USD

Laagste 888 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

19

Buy

0

Hold

0

Sell

Technische score

By Trading Central

732.41 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.